AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06651866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-CMG
Description: Liposomal mitoxantrone hydrochloride injection (Doxorubicin®): Used after dilution with 250mL of 5% glucose injection (50mg/mL), with an intravenous drip time of at least 60 minutes.~* Level 1: 12mg/m2, IV drip, day 4;~* Level 2: 18mg/m2, IV drip, day 4; Decitabine: 25mg, IV drip, days 1-3; Cytarabine: 10mg/m2, every 12 hours, IV drip, days 4-10; G-CSF: 300 ug, IV drip, days 1-5; Each cycle is 4 weeks, with a total of 2 cycles, and DLT is observed in the first cycle.~Note: Patients who achieve CR (Complete Remission) and PR (Partial Remission) in the first cycle can continue with the original dose for one more cycle, and then the investigator decides whether to continue this regimen or choose another regimen for maintenance therapy; Patients with NR (No Remission) in the first cycle will be withdrawn from this study.
Study NCT05676177 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultra Low Dose CT
Description: * Two immediately consecutive scans with either one or two breath-holds~* First scan (ULD_DECT_1) 140 kilovolt peak (kVp) - fixed current 10 or 20 milliampere (mA) (if body mass index (BMI)>30), that is 5 or 10 mAs~* Second scan (ULD_DECT_2) 80 kVp - fixed current 20 or 40 mA (if BMI>30), that is 10 or 20 mAs
Study NCT05676177 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fat quantification MRI
Description: Dual echo scans, as well as proton density fat fraction (PDFF) scans, will be performed to assess liver fat fraction
Study NCT06120374 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy
Description: For participants eligible for enrollment, radiotherapy was started within 4-6 weeks after surgery. Rotational intensity-modulated radiotherapy (VMAT) with daily image-guided radiotherapy (Daily IGRT) technique was used.~Range of irradiation (patients were randomized into two groups - expanded field irradiation group and involved field irradiation group)
Study NCT06120374 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: For patients eligible for enrollment, postoperative adjuvant chemotherapy was initiated at about 4-6 weeks after surgery, for a total of 4 cycles, with the chemotherapy regimen of gemcitabine + cisplatin. Administration: Gemcitabine 1,000 mg/m2 on days 1 and 8 (completed within 30-60 minutes), cisplatin 70 mg/m2 on day 1.
Study NCT06120374 — intervention group
Intervention type: DRUG
Intervention: Immunotherapy
Description: For patients eligible for enrollment, sequential adjuvant immuotherapy was initiated at about 4-6 weeks after surgery, Immunotherapeutic agents include (PD-1/PD-L1) to be used every 21 days postoperatively for one year.
Study NCT04818853 — intervention group
Intervention type: OTHER
Intervention: Observation to monitor patients for these infections
Description: We will be receiving discarded specimens weekly. From these we are going to identify these various potential infections.
Study NCT05060029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus Species
Description: Lactobacilli containing suppositories have been successfully used in the past to maintain the vaginal environment and for treatment of infections like BV. Some of the Lactobacilli species that have been used include Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus gasseri and Lactobacillus plantarum, none of which demonstrated any safety concerns. The investigational product, which contains a Lactobacilli complex as its main component, has already been marketed as a tool to maintain vaginal microbial balance, pH and the prevention of microbial infection, thus there are no additional safety concerns or risks involved in this clinical trial design.
Study NCT05060029 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Coconut Oil Fatty Acids
Study NCT06339372 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Standard feeding
Description: Patients received only standard feeding with caloric distribution (45%-50% carbohydrates,20_35% from fats and 10-35% from protein)
Study NCT06339372 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 and dipeptiven
Description: Patients received perioperative supplementation with omega 3 and dipeptiven (immunonutrition mixture) plus standard feeding.
Study NCT06188143 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ibuprofen-Paracetamol
Description: Ibuprofen 40mg and Paracetamol 500mg per oral, single dose each, in study group 30minutes before hysteroscopic procedure
Study NCT05727124 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Poul Gjessing
Description: maxillary canine retraction
Study NCT05727124 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T loops
Description: T loops
Study NCT04791163 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Socket evaluation
Description: The subject will wear the socket for 4 weeks, and then reply questionnaires and achieve a 2-minute walking test
Study NCT04791163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Socket evaluation
Description: The subject will wear the socket for 4 weeks, and then reply questionnaires and achieve a 2-minute walking test
Study NCT05430997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOB Warming Unit (WU505) + Inflatable Warming Blanket
Description: The inflatable warming method (Inflatable Warming Unit (IOB Warming Unit, WU505) + Inflatable Warming Blanket (IOB Warming Blanket)) is a common clinical warming technique in anesthesiology, which is well tolerated by patients and safe and effective. The anesthesiology department has established standard operating procedures for the above-mentioned non-invasive operations.
Study NCT05430997 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cover with a quilt from the neck to both feet
Description: The patient was covered with a quilt from the neck to both feet after entering the operating room.
Study NCT05659186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg IV Q3W
Study NCT05659186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 12mg PO QD
Study NCT05659186 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Multimodal Radiotherapy
Study NCT05647148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Relaxation Exercises
Description: In the first part of this audio material, which consists of three parts; The definition of deep relaxation, its purpose and points to be considered during exercise are included.~The second part, consisting of an average of thirty minutes, includes the explanation of relaxation exercises with verbal commands accompanied by the sound of the stream.~In the last part, there is only relaxation music without any commands.
Study NCT04065672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose IL-2
Description: After a 4-week screening period, patients received IL-2 at a dose of 1 million IU subcutaneously every other day. After the initiation of the therapy, patients could continue with concurrent medication but were prohibited from changing or adding immunosuppression therapy during the course of the study with a 12-week observational followed up.
Study NCT04065672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After a 4-week screening period, patients received placebo subcutaneously every other day. After the initiation of the therapy, patients could continue with concurrent medication but were prohibited from changing or adding immunosuppression therapy during the course of the study with a 12-week observational followed up.
Study NCT05402488 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Auditory stimulation
Description: Auditory stimulation during sleep
Study NCT05402488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory stimulation
Description: Auditory stimulation during sleep
Study NCT04988581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensively integrated care of microvascular risk factors in the intervention group
Description: The intensively integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment for diabetes and comorbidities in a primary care setting, will be delivered by trained primary care physicians, health managers and diabetes specialists. Diabetic microvascular risk factors (glycated hemoglobin \[HbA1C\], urinary albumin-to-creatinine ratio \[ACR\], blood pressure \[BP\], estimated glomerular filtration rate \[eGFR\], uric acid \[UA\] and low-density lipoprotein cholesterol \[LDL\]) will be tested every 3 month for the intervention group and clinical treatment decisions based on the test results will be implemented accordingly when necessary. The intensively integrated care intervention will last for 36 months. HbA1C, ACR, BP, eGFR, UA, LDL, other variables and co-morbidities will be measured at baseline and follow-up visits every 3 month.
Study NCT06456502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive neuromodulation
Description: The treatment plan of non- invasive neuromodulation will be applied for two months, with a frequency of 2 weekly sessions of one hour duration, until completing a total of 15 sessions for each patient. The sessions will always be applied in the same time slot of the day (to avoid influence on the measurements, specially cortisol).
Study NCT06456502 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment plan of placebo will be applied for two months, with a frequency of 2 weekly sessions of one hour duration, until completing a total of 15 sessions for each patient. Participants will be attached to the neuromodulation machine, however, the cable will not be connected. Participants will not be able to see the machine connections. The sessions will always be applied in the same time slot of the day (to avoid influence on the measurements, specially cortisol).
Study NCT05240391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine Hydrochloride
Description: Midodrine hydrochloride for PICD prevention
Study NCT05240391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Albumin 20%
Description: Human ALbumin 20% for prevention of paracentesis induced circulatory disturbance
Study NCT06393699 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NCCL restoration using resin composite materials
Description: different types of resin composite restorations will be used to restore NCCL
Study NCT06492746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HemoSphere Advanced Monitoring Platform with Acumen IQ sensor and Tissue Oximetry Monitoring
Description: The arterial line with Acumen IQ sensor and Foresight Elite sensor will be connected to the HemoSphere monitor with laptop displaying the CAI parameter.
Study NCT05626868 — intervention group
Intervention type: DEVICE
Intervention: Intra abdominal pressure measurement
Description: Device: Biometrix - Intraabdominal pressure monitoring set Intraabdominal pressure monitoring with the intended set in values of milimeters of mercury (mmHg) in real time.
Study NCT06271746 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FibroNova (Active mode)
Description: FibroNova neurostimulator of conditional pain modulation (CPM)
Study NCT06271746 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: FibroNova (Sham mode)
Description: FibroNova neurostimulator with an electrical output not intended for neurostimulation
Study NCT04766840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T cells
Description: Drug: IM73 CAR-T Cells Drug: Fludarabine Two days before cell infusion, patient will be treated with fludarabine for 3 days Drug: Cyclophosphamide: Two days before cell infusion, patient will be treated with Cyclophosphamide for 3 days
Study NCT04591353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PENG Block
Description: The pericapsular nerve group (PENG) block is a novel regional anesthesia technique for providing analgesia after hip fractures and hip arthroplasties.
Study NCT04591353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 2-3 cc of 2% lidocaine and NO bolus of bupivacaine will be injected.
Study NCT05459896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Training
Description: Participants who exhibit both physical and psychosocial distress will be recommended to receive physical activity intervention. An approach of adding game mechanics into an interactive environment that combines live action and an award system will be integrated into the intervention. The physical training involves 15-min resistance training and 30-min interactive cardio dancing each with beginner and advanced levels. Participants are recommended to start with the beginner level and do the exercises on regular intervals during the intervention period. The Light Detection and Ranging (LiDAR) motion sensor with tablet-based console and the full-body tracking sensor will be used to capture real-time data on participants' human body movements in order to enhance understanding of performance. Participants will get a commercial wearable sensor. Participants will be asked to wear the sensor at all times and sync the data with the Smart Health Platform to self-monitor daily condition.
Study NCT05459896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Intervention
Description: Participants who exhibit psychosocial distress will be recommended to receive mindfulness-based intervention which is designed based on the concept of validated Mindfulness-Based Stress Reduction (MBSR) combined with techniques from Mindfulness-Based Cognitive Therapy (MBCT). The intervention consists of 10 sessions, each session has different main themes and associated activities including body scan, mindful eating, abdominal breathing, chair yoga, awareness of breathing, mindful walking, breathing, body and emotions, yoga stretching, mindful listening and choiceless awreness. The materials will be delivered in the format of animation videos. Participants will be asked to complete one session per week.
Study NCT05459896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Conservation Techniques
Description: Participants who exhibit physiological symptoms will be recommended to receive energy savings intervention which is co-developed by the local Occupational Therapy Association. The intervention consists of six session, each session has different topics and associated energy savings techniques related to particular circumstances, such as the six principle of energy conservation, application of energy conservation in the domains of self-care, household tasks, outdoor activities and work. The materials will be delivered in the format of animation videos. Participants will be asked to complete one session per week. Revision quiz will be given to understand the learning progress of participants.
Study NCT04986267 — intervention group
Intervention type: OTHER
Intervention: ACL Rupture
Description: Female, aged 18-40 years of age with an acute ACL rupture of the knee that occurred within the last 3 months, who presented to a sports or orthopaedic clinic
Study NCT05046561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: STRI Formula
Description: STRI Formula is a combination of food based substances (botanicals, vitamins, minerals, and protein) with multiple, distinct, synergistic, direct and indirect antiviral effects against SARS-CoV-2
Study NCT05046561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule
Study NCT04417699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS 102
Description: Oral medication over Days 1-5
Study NCT04417699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered by intravenous infusion over 2 hours on day 1
Study NCT05684393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: frequency distribution type
Description: One group is fitted using channel filterbank frequency distribution based on anatomy data extracted from post-OP CT measurements. The second (control) group is fitted with the standard frequency distribution used in MAESTRO 9 fitting software.
Study NCT05684393 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: frequency distribution type
Description: One group is fitted using channel filterbank frequency distribution based on anatomy data extracted from post-OP CT measurements. The second (control) group is fitted with the standard frequency distribution used in MAESTRO 9 fitting software.
Study NCT05757544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Ganaxolone
Description: IV Ganaxolone will be administered.
Study NCT05757544 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo
Description: IV Placebo will be administered
Study NCT05338814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scapular corrective exercises
Description: 40 minutes each, three times a week for six weeks
Study NCT05338814 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional neck exercises
Description: 40 minutes each, three times a week for six weeks
Study NCT05338814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional neck exercises
Description: 40 minutes each, three times a week for six weeks
Study NCT04808661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic endovascular aortic repair plus optimal medical therapy
Description: Endovascular treatment (thoracic endovascular aortic repair) plus optimal medical therapy
Study NCT04808661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical therapy
Description: Optimal medical therapy (strictly control of their blood pressure and heart rate)
Study NCT05190497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: Maximal respiratory pressure and reflecting muscles strength were measured by a mouth pressure meter
Study NCT04989868 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-Nasal Afferent Loop Decompression
Description: A 14Fr silicon tube with multiple side holes within the range of 15 cm from the tip will be placed into the afferent jejunal limb with its end close to the pancreaticojejunostomy (\<3 cm) during the surgery. Continuous closed negative-pressure suction will be applied to that tube for 72 hours and after that the nasogastric tube will be removed. No nasogastric tube will be placed, or the nasogastric tube will be removed immediately after extubation.
Study NCT04989868 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Without Trans-Nasal Afferent Loop Decompression
Description: No decompression tube will be placed. No nasogastric tube will be placed, or the nasogastric tube will be removed immediately after extubation.
Study NCT05408442 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04441086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eMotion
Description: Content is delivered within the context of emotion provoking situations common in those recovering from a first MI and in maintaining MVPA. The new on-demand access to asynchronous content sessions provides didactic presentation of video and written material based on weekly needs assessments. Weekly scheduled synchronous video chat sessions, led by a nurse interventionist, will provide further individualization and application of content materials.
Study NCT04441086 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Active Control
Description: The attention control group will receive their usual cardiac rehabilitation and a comparable dose matched (to that of the eMotion intervention) of healthy living web content and video chat with a nurse.
Study NCT04946981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Turmipure Gold®
Description: TPG: Turmipure GOLD® - 1 capsule per day - as prescribed
Study NCT04946981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Placebo: colored acacia gum - 1 capsule per day - as prescribed
Study NCT04673019 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nurse AMIE (Addressing Metastatic Individuals Every day)
Description: Supportive Care Platform (behavioral interventions that are offered based on answers to daily symptom rating questions). Interventions offered include walking, balance, strength exercise, guided relaxation, CBT, DBT, soothing music.
Study NCT04673019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse AMIE (Addressing Metastatic Individuals Every day)
Description: Supportive Care Platform (behavioral interventions that are offered based on answers to daily symptom rating questions). Interventions offered include walking, balance, strength exercise, guided relaxation, CBT, DBT, soothing music.
Study NCT05461508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amoxicillin combined with vonoprazan and fucoidan
Description: Fucoidan was used in combination with amoxicillin and vonoprazan. The purpose of this study was to explore the effect of fucoidan on the eradication rate of Helicobacter pylori and the intestinal flora of subjects.
Study NCT05461508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin combined with vonoprazan
Description: Amoxicillin and vonoprazan were used as the study control group
Study NCT04682054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ocular surgery
Description: surgery to remove the pathological eye tissue